| Abstract |
Abstract Objective: To observe the clinical efficacy of ziprasidone combined with quetiapine in the treatment of excitement and agitation in acute phase of schizophrenia. Methods: 120 cases of patients with excitement and agitation in acute phase of schizophrenia were randomly divided into the control group and the observation group, 60 cases in each group. The control group was treated with Quetiapine Fumarate Tablets orally, and the observation group was additionally treated with Ziprasidone Hydrochloride Capsules on the basis of the treatment in control group. The two groups were treated continuously for 4 weeks. The Positive and Negative Syndrome Scale (PANSS) score, the clinical global impression-severity of illness (CGI-SI) score, the Excited Component of PANSS (PANSS-EC) score, The MATRICS Consensus Cognitive Battery (MCCB) score, personal and social performance (PSP) score and SF-36 quality of life score were used to evaluate the curative effect. Levels of serum brain-derived neurotrophic factor (BDNF), glial derived neurotrophic factor (GDNF), nerve growth factor (NGF), interleukin -1 β (IL-1β) and tumor necrosis factor α (TNF- α) were detected, and the safety was evaluated by the Treatment Emergent Symptom Scale (TESS) and regular monitoring of blood routine, electrocardiogram and liver function. Results: After 4 weeks of treatment, the total PANSS score, CGI-SI score, PANSS-EC score and MCCB score of the observation group were significantly lower than those of the control group (P<0.05), while PSP score and SF-36 quality of life score were significantly higher than those of the control group (P<0.05). After 4 weeks of treatment, the serum levels of BDNF, GDNF and NGF in the observation group were significantly increased, and the levels of IL-1β and TNF-α were significantly decreased (P<0.05). Adverse reactions in the two groups were mild, and after 4 weeks of treatment, there was no significant difference in the TESS score and the total incidence of adverse reactions between the two groups (P>0.05). There were no abnormalities of blood routine, electrocardiogram and liver function. Conclusion: The application of ziprasidone combined with quetiapine in the treatment of patients with excitement and agitation in acute phase of schizophrenia can improve the levels of serum BDNF, GDNF and NGF, effectively alleviate the symptoms of schizophrenia, excitement and agitation, and improve the cognitive function, social function and quality of life, without significantly increasing the adverse reactions.
|